JP2019536462A5 - - Google Patents

Download PDF

Info

Publication number
JP2019536462A5
JP2019536462A5 JP2019530105A JP2019530105A JP2019536462A5 JP 2019536462 A5 JP2019536462 A5 JP 2019536462A5 JP 2019530105 A JP2019530105 A JP 2019530105A JP 2019530105 A JP2019530105 A JP 2019530105A JP 2019536462 A5 JP2019536462 A5 JP 2019536462A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
genome editing
cas9 protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019530105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536462A (ja
JP7272952B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/064720 external-priority patent/WO2018106693A1/en
Publication of JP2019536462A publication Critical patent/JP2019536462A/ja
Publication of JP2019536462A5 publication Critical patent/JP2019536462A5/ja
Priority to JP2022208855A priority Critical patent/JP2023052089A/ja
Application granted granted Critical
Publication of JP7272952B2 publication Critical patent/JP7272952B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019530105A 2016-12-05 2017-12-05 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法 Active JP7272952B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022208855A JP2023052089A (ja) 2016-12-05 2022-12-26 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662430154P 2016-12-05 2016-12-05
US62/430,154 2016-12-05
US201762503640P 2017-05-09 2017-05-09
US62/503,640 2017-05-09
PCT/US2017/064720 WO2018106693A1 (en) 2016-12-05 2017-12-05 SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022208855A Division JP2023052089A (ja) 2016-12-05 2022-12-26 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法

Publications (3)

Publication Number Publication Date
JP2019536462A JP2019536462A (ja) 2019-12-19
JP2019536462A5 true JP2019536462A5 (https=) 2021-01-21
JP7272952B2 JP7272952B2 (ja) 2023-05-12

Family

ID=60972337

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530105A Active JP7272952B2 (ja) 2016-12-05 2017-12-05 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法
JP2022208855A Withdrawn JP2023052089A (ja) 2016-12-05 2022-12-26 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022208855A Withdrawn JP2023052089A (ja) 2016-12-05 2022-12-26 内因性および起源DNAのワンショットガイドRNA(ogRNA)標的化のためのシステムおよび方法

Country Status (9)

Country Link
US (6) US9963719B1 (https=)
EP (1) EP3548614A1 (https=)
JP (2) JP7272952B2 (https=)
KR (1) KR102604903B1 (https=)
CN (1) CN110168084A (https=)
AU (1) AU2017373797B2 (https=)
CA (1) CA3046076A1 (https=)
MX (2) MX2019006475A (https=)
WO (1) WO2018106693A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
WO2017075475A1 (en) * 2015-10-30 2017-05-04 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
MA50877A (fr) 2017-11-21 2020-09-30 Bayer Healthcare Llc Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
EP3723813A4 (en) * 2017-12-15 2021-10-06 Regents of the University of Minnesota GENOMIC CRISPR MEDIATION EDITING WITH VECTORS
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
WO2020055748A1 (en) * 2018-09-10 2020-03-19 The Regents Of The University Of California Modulators of cas9 polypeptides and methods of use thereof
WO2020176552A1 (en) 2019-02-25 2020-09-03 Editas Medicine, Inc. Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
WO2020186059A2 (en) * 2019-03-12 2020-09-17 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
EP3990636A1 (en) 2019-06-28 2022-05-04 CRISPR Therapeutics AG Materials and methods for controlling gene editing
WO2021053582A1 (en) * 2019-09-18 2021-03-25 Crispr Therapeutics Ag All-in-one self inactivating crispr vectors
WO2021062201A1 (en) * 2019-09-25 2021-04-01 Spotlight Therapeutics Compositions and methods for nucleoprotein targeting and expression
US20230203220A1 (en) * 2020-05-29 2023-06-29 Regents Of The University Of Minnesota Copolymers for intracellular therapeutic nucleic acid payload delivery
CA3200815A1 (en) * 2020-12-03 2022-06-09 Benjamin OAKES Compositions and methods for the targeting of bcl11a
EP4323522A1 (en) 2021-04-16 2024-02-21 Editas Medicine, Inc. Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
WO2025179057A1 (en) * 2024-02-21 2025-08-28 The Regents Of The University Of California In vivo modification of cell genomes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
MX2016007325A (es) 2013-12-12 2017-07-19 Broad Inst Inc Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
WO2015138510A1 (en) 2014-03-10 2015-09-17 Editas Medicine., Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
CA2963820A1 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
EP3265559B1 (en) * 2015-03-03 2021-01-06 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
US20190002920A1 (en) 2015-04-30 2019-01-03 The Brigham And Women's Hospital, Inc. Methods and kits for cloning-free genome editing
WO2016183438A1 (en) 2015-05-14 2016-11-17 Massachusetts Institute Of Technology Self-targeting genome editing system
WO2016186772A2 (en) 2015-05-16 2016-11-24 Genzyme Corporation Gene editing of deep intronic mutations
US11530421B2 (en) * 2016-02-01 2022-12-20 The Regents Of The University Of California Self-inactivating endonuclease-encoding nucleic acids and methods of using the same
WO2017173004A1 (en) * 2016-03-30 2017-10-05 Mikuni Takayasu A method for in vivo precise genome editing

Similar Documents

Publication Publication Date Title
JP2019536462A5 (https=)
JP2021176301A (ja) 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系
US20200340012A1 (en) Crispr-cas genome engineering via a modular aav delivery system
CN111757889A (zh) 新型CRISPR/Cas12f酶和系统
MX2023002848A (es) Enzimas modificadoras del acido desoxirribonucleico (adn) y fragmentos activos y sus variantes y metodos de uso.
JP2022529329A (ja) 人工的に構築されたrna編集酵素による部位特異的rna編集および関連使用
JP2019531068A5 (https=)
JP2019526248A5 (https=)
JP2017513479A5 (https=)
JP2018534950A5 (https=)
IL309801B1 (en) Using nucleosome interacting protein domains to enhance targeted genome modification
KR20180012834A (ko) 두 개의 벡터로부터 발현된 Cas9 단백질을 이용한 유전자 발현 조절 방법
JP2017018125A5 (https=)
JP2018537087A5 (https=)
DE60042969D1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
DK1641818T3 (da) Polypeptider der har bindingsaffinitet for HER2
WO2005080556A3 (en) Virus purification methods
JP2015532654A5 (https=)
JP2018520997A5 (https=)
DE602005016712D1 (de) Rter dna
ZA200007403B (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals.
JP2015513897A5 (https=)
JP2015521465A5 (https=)
JP2011521661A5 (https=)
MX2021004714A (es) Proteina cas9 modificada, y uso de la misma.